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Dengue virus (DENV), a globally emerging cause of 
undifferentiated fever, has been documented in the heavily 
urbanized western coast of Sri Lanka since the 1960s. 
New areas of Sri Lanka are now being affected, and the 
reported number and severity of cases have increased. 
To study emerging DENV in southern Sri Lanka, we 
obtained epidemiologic and clinical data and acute- and 
convalescent-phase serum samples from patients >2 years 
old with febrile illness. We tested paired serum samples for 
DENV IgG and IgM and serotyped virus by using isolation 
and reverse transcription PCR. We identifi ed acute DENV 
infection (serotypes 2, 3, and 4) in 54 (6.3%) of 859 patients. 
Only 14% of patients had clinically suspected dengue; 
however, 54% had serologically confi rmed acute or past 
DENV infection. DENV is a major and largely unrecognized 
cause of fever in southern Sri Lanka, especially in young 
adults.
Dengue virus (DENV), with 4 antigenically distinctserotypes (DEN1–4), is the most common cause 
of arboviral disease; ≈50 million cases of dengue occur 
annually in >100 countries (1). Manifestations of dengue 
infection range from asymptomatic or mild febrile illness 
to circulatory failure and death from dengue hemorrhagic 
fever (DHF). Urbanization and geographic expansion of 
the primary vector for DENV, Aedes aegypti, have fueled 
the current global dengue pandemic (2).
DENV has been documented in the Indian subcontinent 
since the 1960s, and there are recent reports of DENV in 
new areas and of severe disease (2,3). Epidemic dengue 
was fi rst recognized in Colombo, the capital of Sri Lanka, 
in 1965–1966 (4). Outpatient, clinic-based surveillance 
at Colombo’s Lady Ridgeway Children’s Hospital 
during 1980–1984 found dengue accounted for 16% of 
acute febrile illness, among which 66% were secondary 
(recurrent) dengue cases. A 1980–1985 school-based 
study found a baseline DENV seroprevalence of 50% in 
Colombo and a 6-month dengue incidence of 15.6%, of 
which 37% were secondary cases (4). In the early 1980s, 
severe dengue was rare in Sri Lanka: <10 reported cases 
were DHF (4). However, since 1989, many cases of DHF 
have been reported from the heavily urbanized western 
coastal belt of Sri Lanka, which includes Colombo (5), and 
cases have recently been reported elsewhere in the country.
DENV began emerging in southern Sri Lanka recently. 
To defi ne the epidemiology of dengue in this previously 
unstudied region, we prospectively enrolled patients 
seeking care for acute febrile illness at a local hospital. 
Study participants lived in Galle, a seaport city (population 
100,000), and the surrounding coastal plain and heavily 
vegetated foothills at the southernmost tip of the island 
nation. During the study months, the temperature ranged 
from highs of 27.5°C to 32°C and lows of 24°C to 26°C, 




During March–October 2007, we recruited patients 
in the emergency department, acute care clinics, and 
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adult and pediatric wards of Teaching Hospital Karapitiya 
in Galle, the largest (1,300-bed) hospital in southern Sri 
Lanka. Consecutive febrile (>38°C tympanic) patients >2 
years old without trauma or hospitalization within 7 days 
were eligible for study participation. Study doctors verifi ed 
eligibility and willingness to return for convalescent-phase 
follow-up and obtained written consent from patients or 
from parents (for patients <18 years old) and assent from 
those >12–17 years old. The institutional review boards of 
the University of Ruhuna, Johns Hopkins University, and 
Duke University Medical Center approved the study.
Study personnel recorded epidemiologic and clinical 
data on a standardized form. Study doctors obtained 
blood for on-site, clinician-requested testing and off-site, 
research-related testing. Patients returned for clinical and 
serologic follow-up 2–4 weeks later or were visited in their 
home if unable to return and their address was known. 
Blood and serum samples were stored promptly at −80°C 
and shipped on dry ice to the University of North Carolina 
School of Medicine (laboratory of A. de S.), where paired 
serum samples were tested by ELISA and acute-phase 
serum samples were cultured and tested by PCR.
Serologic Testing for Dengue
IgM ELISA
We performed dengue IgM capture ELISA as 
described (6), except we used anti-fl avivirus monoclonal 
antibody (mAb) 4G2 followed by enzyme-conjugated 
goat anti-mouse IgG to detect captured DENV antigen. 
In brief, 96-well plates were coated (overnight, 4°C) with 
100 μL/well (1 ng/μL) of goat anti-human IgM (Sigma, 
St. Louis, MO, USA) at a concentration of 0.1 mol/L in 
carbonate buffer (pH 9.6). Plates were washed 3× in Tris-
buffered saline with 0.2% Tween 20 (TBST) and blocked 
with 200 μL/well of 1× Tris-buffered saline with 0.05% 
Tween 20 and 3% nonfat dry milk. Paired serum samples 
were tested on the same plate. Diluted serum (1:50) was 
loaded in duplicate and incubated (37°C, 1 h) to capture 
IgM antibody. Unbound antibody was washed, and wells 
were successively incubated with DENV antigen (mix of 
serotypes DEN1–4), mouse anti-fl avivirus 4G2 mAb, and 
human-absorbed alkaline phosphatase (AP)–conjugated 
goat anti-mouse IgG antibody (Sigma). Optical density 
(OD) was measured at 405 nm after fi nal incubation with 
AP substrate.
IgG ELISA
Dengue IgG ELISA was performed as described (7). 
Plates were coated overnight (4°C) with 100 μL/well of 
mouse anti-fl avivirus 4G2 mAb at a concentration of 0.1 
mol/L in carbonate buffer (pH 9.6) and then washed 3× 
in TBST. Plates were then blocked with standard diluents 
and successively incubated (37°C, 1 h) with DEN1–4 
antigen, diluted serum (1:100) in duplicate wells, and 
AP-conjugated goat anti-human IgG (Fc portion), with 3 
washings (TBST) between incubations. Plates were read at 
405 nm after a fi nal incubation with AP substrate (15 min, 
room temperature, in the dark).
Serologic Interpretation
We defi ned acute dengue as IgG seroconversion 
(acute-phase OD <0.20 and convalescent-phase OD >0.20) 
or as a substantial increase in antibody titer (convalescent-
phase IgG OD >0.30 or IgM OD >0.20 than acute-
phase). Acute primary (fi rst episode) and acute secondary 
(recurrent) dengue were distinguished by the absence or 
presence of IgG (OD <0.35 and >0.35, respectively) in 
acute-phase serum samples. The presence of IgG without 
a substantial increase in titer defi ned past dengue infection. 
Seroprevalence was defi ned as the presence of IgG (OD 
>0.20) in acute-phase serum samples; other samples were
seronegative. For each ELISA, we used 2 negative control
human serum samples, each tested in duplicate. Positive
cut-off values were determined during assay validation and
were based on the mean OD +2 SD for negative control
serum specimens.
Isolation of Dengue
Individual 15-μL aliquots of undiluted acute-phase 
serum (from all patients with confi rmed acute dengue 
as well as negative and positive controls) were each 
mixed with 185 μL of Eagle minimal essential medium 
supplemented with 2% fetal bovine serum, and then each 
was added to C6/36 cells (27°C, 5% CO2). After 7 and 
10 days, cells were fi xed and a direct immunofl uorescent 
antibody assay was performed by using anti-dengue mAb 
(2H2-Alexa488) (8). Positive samples were centrifuged 
(1,500 × g, 5 min). Supernatants containing virus were 
supplemented with 20% fetal bovine serum, divided into 
aliquots, and preserved at −80°C.
Dengue Virus Neutralization
We tested the convalescent-phase serum samples from 
35 patients with serologically defi ned acute dengue. Dengue 
neutralizing antibodies were detected by using a fl ow 
cytometry–based assay as described (9). In brief, serially 
diluted immune serum samples were incubated with each 
of the 4 dengue serotypes (37°C, 1 h). Next, the virus and 
serum mixture was added to a human monocyte cell line 
(U937DC-SIGN) that was engineered to express the dengue 
receptor DC-SIGN and incubated with 5% CO2 (37°C, 24 
h). The cells were washed, fi xed, and stained with Alexa 
488–conjugated anti-dengue mAb 2H2. The percentage of 
infected cells was measured by fl ow cytometry. GraphPad 
Prism 4 for Windows (www.graphpad.com/welcome.htm) 
and nonlinear regression analysis were used to calculate 
50% neutralization values.
PCR for DENV
To yield cDNA, we used RNA eluted serum samples 
(QIAmp Viral RNA Mini Kit; QIAGEN, Valencia, CA, 
USA) from 25–140 μL of acute-phase serum samples, 
reverse transcriptase (RT), and DENV downstream 
consensus primer D2 or random primers. To confi rm and 
serotype DENV, we used consensus primers D1 and D2 
to amplify cDNA by standard PCR; positive fi rst-round 
PCR products were diluted 1:100 and used as template in 
second-round PCR with consensus primer D1 and nested 
serotype DEN1–4 type-specifi c primers (10). Negative 
controls were included for the RT and PCR steps. The 
negative control for the RT step consisted of a sample to 
which all reagents, except RNA, were added. The negative 
control step for PCR consisted of a sample to which all 
reagents, except cDNA, were added.
Statistical Analysis
Proportions were compared by the χ2 test or Fisher 
exact test and continuous variables by Student t test or the 
rank sum test, if not normally distributed. Analyses were 




Paired serum samples to identify acute and past dengue 
were available for 859 (79.6%) of 1,079 patients enrolled. 
The likelihood of follow-up did not differ by age (p = 
0.30), sex (p = 0.22), or level of education (p = 0.74). Most 
(90.2%) patients reported rural residence, and follow-up 
was more likely among rural (80.6%) than urban (69.5%) 
dwellers (p = 0.008). The reported duration of fever and 
illness was similar in patients who did and did not return 
for follow-up. 
Among the 859 patients with paired serum samples, 
61.2% were male, and the median age was 30.7 years 
(interquartile range [IQR] 19–48 years), which did not 
differ by sex (p = 0.97). The median reported duration 
of fever and of illness before seeking medical care was 3 
days (IQR 2–5 and 2–7 days, respectively). Many patients 
(36.3%) reported having taken an antimicrobial drug for 
the illness. The median time between acute-phase and 
convalescent-phase follow-up was 21 days (IQR 15–32 
days).
Acute Dengue
Acute dengue occurred during each month of the 
study and accounted for 3.0% (May) to 11.1% (October) 
of acute febrile illnesses. Fifty-four patients (6.3%) had 
acute dengue (27 primary and 27 secondary infections). 
Of patients >18 and <18 years old, 48 (7.0%) and 6 
(3.5%), respectively, had acute dengue (p = 0.09). The age 
distribution of patients with and without acute dengue is 
shown in Figure 1. The median age of patients with acute 
dengue was 27.6 years (IQR 22–45 days), and a similar 
proportion were male versus female (p = 0.26).
The clinical features of patients with and without acute 
dengue are detailed in Table 1. Headache was the most 
frequent (75.9%) symptom, and lethargy and muscle and 
joint pain were also reported by >50% of patients with 
dengue; however, these symptoms were just as frequent 
in patients without dengue. Patients with dengue were less 
likely than those without it to report cough and sore throat 
and to have lymphadenopathy, but they were more likely 
to have conjunctivitis. Although gastrointestinal symptoms 
and signs were uncommon overall, diarrhea, jaundice, 
hepatomegaly, and abdominal tenderness occurred more 
frequently in dengue patients. Patients with acute dengue 
had statistically signifi cantly lower leukocyte and platelet 
counts than patients without dengue. No dengue patients 
had petechiae. 
Only 3 acute dengue patients (men 23–27 years old; 2 
with secondary and 1 with primary infection) had platelet 
Figure 1. Age distribution of patients with and 
without acute dengue, southern Sri Lanka, 
2007.
counts consistent with DHF (<100,000/μL) (11). At 
admission, 2 of the 3 men reported myalgia and arthralgia; 
all 3 had headache, leukopenia (leukocytes 2,400–3,600 
cells/μL), severe thrombocytopenia (platelets 19,000–
47,000/μL), and compensated shock (blood pressure 100–
110/70–80 mm Hg, with heart rate 88–100 beats/min). 
Additional laboratory testing only included determination 
of transaminase levels, which were elevated in the 1 patient 
in whom they were evaluated. All 3 patients were well at 
follow-up.
Patients with acute dengue were more likely than those 
with other causes of fever to be hospitalized (92.6% vs. 
71.3%; p = 0.001), but their duration of stay was similar 
(median 5 vs. 4 days [IQR 3–7 and 3–6 days, respectively]; 
p = 0.23). A presumptive clinical diagnosis was available 
for 791 patients, including 50 with acute dengue. Few adults 
and children were suspected to have acute dengue on the 
basis of clinical features (3.3% vs. 1.2%, respectively; p = 
0.16), and only 7 of the 23 patients (all adults) with clinically 
suspected dengue had laboratory-confi rmed infection 
(positive predictive value 30.4%, 95% CI 27.2–33.6). 
Clinical diagnosis also had poor sensitivity (14.0%; 95% CI 
11.6–16.4) and high specifi city (97.8%; 95% CI 96.8–98.9). 
Compared with other patients, those with suspected dengue 
were more likely to be admitted to the hospital (70.4% 
vs. 95.7%; p = 0.008) and less likely to be treated with 
antimicrobial drugs (72.6% vs. 20.0%; p = 0.02). However, 
50.0% of those with confi rmed acute dengue reported taking 
antimicrobial drugs before seeking medical care.
Clinical illness was similar in patients with primary 
and secondary dengue. Median platelet counts were 
186,000/μL (IQR 153,000–234,000/μL) and 198,000/
μL (IQR 160,000–270,000/μL) for patients with primary 
and secondary dengue, respectively (p = 0.60). Diarrhea 
was more common in patients with secondary than with 
primary dengue (33.3% vs. 11.1%; p = 0.05), as were 
jaundice (14.8% vs. 0.0%; p = 0.04) and hepatomegaly 
(22.2 vs. 0.0%; p = 0.01). The duration of illness before 
Table 1. Clinical characteristics of febrile patients with and without acute dengue, southern Sri Lanka, 2007* 
Characteristic Acute dengue, n = 54 Not acute dengue, n = 805 p value 
Symptoms
Headache 75.9  78.1  0.70 
Sore throat 13.0  29.3  0.01 
Cough 35.2  58.5  0.001 
Dyspnea 15.1  16.7  0.76 
Joint pain 50.9  44.3  0.35 
Muscle pain 57.7  48.7  0.21 
Lethargy 68.6  66.6  0.76 
Abdominal pain 25.0  19.0  0.29 
Emesis 43.4  36.9  0.35 
Diarrhea 22.2  10.7  0.01 
Dysuria 16.7  14.4  0.65 
 Oliguria 14.8 9.1 0.17 
Signs
 Mean temperature, C,  SD 38.5  0.70 38.4  0.61 0.66
Mean heart rate, beats/min,  SD 85  17 84  16 0.57
Mean systolic blood pressure, mm Hg,  SD 114  16 111  16 0.32
Mean diastolic blood pressure, mm Hg,  SD 72  16 73  11 0.58
Conjunctivitis 27.8  14.0  0.006 
Pharyngeal erythema or exudates 5.6  14.0 0.08 
Lymphadenopathy 3.7  24  0.001 
Jaundice 7.6  1.4  0.001 
Lung crackles 5.7  14.2 0.08 
Tender abdomen on palpation 18.5 9.4  0.03 
 Hepatomegaly 11.3 5.0 0.05 
Swollen joint 1.9  0.5  0.27 
Rash 5.6  2.3  0.14 
Laboratory parameters 
 Leukocytes/ L, median (IQR) 5,300 (3,600–12,000) 8,000 (5,800–11,100) 0.009 
 ANC/ L, median (IQR) 3,600 (2,304–8,560) 5,396 (3,534–7,980) 0.03 
 ALC/ L, median (IQR) 1,602 (1,044–2,400) 2,085 (1,540–2,829) 0.002 
Hemoglobin, g/dL, mean  SD 12.9  1.6 12.6  1.7 0.25
 Platelets,  1,000/ L, mean (IQR) 190 (156–242) 232 (190–293) 0.0002 
*Values are percentages unless otherwise stated. Leukocytes, white blood cell count; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; 
IQR, interquartile range. 
patients sought care was similar for those with primary and 
secondary dengue. Patients with primary dengue were as 
likely as those with secondary dengue to be admitted to the 
hospital (both 92.6%; p = 1.0) and to remain for a similar 
duration (median 5 days for both [IQR 3–6 and 3–8 days, 
respectively]; p = 0.89).
Acute or Past Dengue
Fifty-four percent (464/859) of the study cohort 
had either acute or past dengue (see Table 2 for patient 
characteristics). The overall seroprevalence was 50.9% 
(437/859 patients) because the 27 patients with acute 
primary infections were seronegative at enrollment. The 
proportion of patients who were seropositive at enrollment 
increased in each older age group, from 9% in those <5 
years old to 72% in those 40–44 years old (Figure 2). 
Overall, seropositivity was more likely in male than in 
female patients (55.9% vs. 42.9%; p<0.0001), and in urban 
than in rural dwellers (75.3% vs. 52.0%; p<0.0001).
Confi rmation of Acute Dengue 
and Serotyping of Virus
We isolated DENV from 12 (22.2%) of the 54 acute 
dengue patients. The likelihood of isolating DENV was 
higher when the patient had fewer reported days of fever 
(median 3 vs. 4 days; p = 0.04), and DENV was isolated 
almost exclusively from patients with primary versus 
secondary dengue (91.7% vs. 8.3%; p = 0.001). 
Dengue PCR results were positive in 19 (35.2%) 
patients; positive results were higher among patients with 
positive versus negative culture results (75.0% vs. 23.8%; 
p = 0.001). Fever duration was similar in patients with 
dengue-positive and -negative PCR results (median 4 
days; p = 0.22). A positive PCR result was not statistically 
more likely in patients with primary versus those with 
secondary dengue (57.9% vs. 42.1%; p = 0.39). PCR 
testing confi rmed serotype DEN2 (2 primary cases), D3 (8 
primary, 7 secondary), and D4 (1 primary, 1 secondary); 
no cases of serotype DEN1 were identifi ed. DENV 
neutralization testing confi rmed the specifi c presence of 
dengue antibodies in 33 (94.3%) of 35 IgG-positive serum 
samples (95% CI 80.8–99.3).
Discussion
We sought to defi ne the epidemiology of dengue in 
the southern tip of Sri Lanka. We prospectively enrolled 
patients with a reproducible criterion (documented fever) 
and rigorously distinguished acute from past infections 
by using paired serum samples. The seroprevalence of 
dengue in our cohort increased with age; however, half 
of those 20–25 years old were seronegative. In contrast, 
50% of children in Colombo are positive for dengue IgG 
antibody by 5 years of age, and >70% have been found 
to be seropositive by 12 years of age (4,12). The high 
proportion of susceptible adults in Galle suggests the recent 
emergence of DENV in this area (4,5).
Table 2. Demographic characteristics of febrile patients with or without evidence of dengue virus infection, southern Sri Lanka, 2007* 
Characteristic Acute dengue, n = 54† Past dengue, n = 410† Not dengue, n = 395† p value 
Median age, years (IQR) 27.6 (22.4–44.5) 41.3 (27.0–53.4) 21.7 (13.3–35.3) 0.0001 
Male 68.5 66.3 54.9 0.002
Residence 0.001
 Rural 86.8 88.2 95.4
 Urban 13.2 11.8 4.6 
Type of work <0.001 
 Home 11.5 25.9 27.8
 Laborer 19.2 32.4 18.3
Farmer, e.g., rice paddy 5.8 3.0 2.3 
 Merchant 3.9 4.0 2.1
 Student 13.5 7.3 37.8
 Other 46.2 27.4 11.8
Swim/bathe/wade in freshwater 0.63 
 None 74.1 73.1 76.4
 River 20.4 13.5 12.2
 Paddy field 3.7 10.8 9.1
 Pond/lake 0 1.0 1.0 
Other 1.9 1.7 1.3
Water source 0.003
Tap 42.6 35.1 25.5
 Boiled 3.7 8.8 10.2 
Well 51.9 54.9 64.4
 Other 1.9 1.2 0 
*Except for median age, data are percentages. IQR, interquartile range. 
†Values are percentages unless otherwise stated. 
Dengue is considered an urban and peri-urban disease, 
and the current pandemic is partly attributed to increasingly 
populous cities (2). We documented cases of acute dengue 
during March–October in rural and semi-urban areas. In 
rural Cambodia, dengue is a major cause of hospitalization 
and death among children, with delays in recognition 
and care-seeking contributing to its impact in rural areas 
(13,14). Discarded water storage jars and concrete water 
tanks are commonly used breeding sites for the vector 
(15), and mosquito populations may be higher in rural 
than urban areas (16). Dengue has also been documented 
in rural Vietnam (17). Control efforts in urban Sri Lanka 
have included covering cement water tanks, which are 
established breeding sites for Aedes spp. (18); however, 
data to direct control efforts in Southern Sri Lanka are 
lacking.
We describe the clinical manifestations of endemic 
dengue in an unselected febrile cohort in southern Sri 
Lanka. Dengue accounted for 6.3% (54/859) of acute 
febrile illnesses in this cohort; serotypes DEN2–4 caused 
illness, with DEN3 being the most frequent. In the cohort 
(predominantly adults who sought care early in illness), 
manifestations of acute dengue were similar to those of 
other causes of fever, except for more diarrhea, jaundice, 
and abdominal tenderness and less cough and sore throat. 
Ramos et al. (19) similarly identifi ed the presence of 
diarrhea and absence of respiratory symptoms as early 
features of confi rmed acute dengue infection in adults; 
however, 53.5% of the patients in that study were excluded 
from analyses because only single serum samples were 
tested. 
We identifi ed a disease spectrum different from that 
of classic severe dengue reported in hospital-based studies 
during epidemics in urban centers (Colombo and Kandy) 
in Sri Lanka (20–22); the spectrum we report is similar to 
that described in studies of acute febrile illness elsewhere 
in Asia. In a report from Singapore, headache, retro-
orbital pain, arthralgia, anorexia, nausea, and vomiting 
were symptoms statistically associated with dengue, but, 
as in our study, the symptoms were common in their 
entire febrile cohort (23). In the same study, signs more 
suggestive of dengue were infrequent: red eyes (33.6% 
of patients), rash (11.2%), and bleeding (7.5%). The only 
signs we found statistically associated with acute dengue 
were jaundice, abdominal tenderness, and hepatomegaly. 
Others have found abnormal test results for liver function 
to be common among patients with secondary dengue (24). 
That we observed jaundice only in secondary cases lends 
credence to the hypothesis that host response to the virus 
may be a major factor in the pathogenesis of dengue (24).
Our fi nding that only 14% of patients with dengue 
were identifi ed clinically is consistent with the recent 
emergence of dengue in southern Sri Lanka. In addition, the 
fi nding emphasizes the diffi culties with clinical diagnosis, 
particularly in unselected patients with recent onset of fever 
(median 3 days) in the absence of a recognized epidemic. 
Clinical acumen is diffi cult to develop when confi rmatory 
testing is not available, even in a subset of patients. This 
fact highlights the need for rapid, accurate point-of-care 
diagnosis (25), which could also limit the frequent use of 
unnecessary antimicrobial drugs. 
A limitation of many studies is that diagnosis of acute 
dengue was made on the basis of a single serum sample. 
In studies of severe dengue in urban Sri Lanka (20,22) and 
in a more recent case-control study of dengue (26), acute 
dengue was defi ned by a positive result from a PanBio 
dual IgM/IgG rapid strip test (PanBio Pty Ltd., Brisbane, 
Australia) (27), which was performed on a single serum 
sample obtained on day 7 of illness. This strategy may be 
adequate during an epidemic in a patient with classic severe 
dengue; however, in a setting of high dengue seroprevalence 
and lower pretest probability (undifferentiated fever, no 
Figure 2. Presence of IgG against 
dengue in febrile patients, by age, 
southern Sri Lanka, 2007.
recognized epidemic), a single positive serologic test result 
may more often denote past dengue, and the true cause of 
illness might remain unrecognized and untreated.
Unique strengths of our study include rigorous 
confi rmation of acute infection by World Health 
Organization criteria (28), a large sample size with 
80% follow-up (critical to reference-standard diagnosis 
and assessment of outcomes), and prospective clinical 
correlation. To confi rm dengue, the World Health 
Organization requires detection of virus by isolation or PCR 
or a 4-fold rise in antibody in paired serum samples. Cases 
with supportive serologic test results (single high antibody 
titer) are considered probable cases because antibody may 
not be present early (poor sensitivity) or may represent past 
infection (poor specifi city) (28). In our study, we would 
have identifi ed only secondary cases if a probable case 
defi nition had been used because IgG is initially absent 
in primary dengue. We assessed paired serum samples 
by using an ELISA comparable to the more diffi cult and 
time-consuming hemagglutinin inhibition test used for 
determining dengue seroprevalence in populations (7) and 
the ELISA used for dengue surveillance in Colombo, Sri 
Lanka (12). A recent systematic review scrutinized clinical 
studies designed to aid clinicians in resource-poor settings 
by identifying features predictive of acute dengue (29). 
Most studies had myriad methodologic fl aws, including 
inadequate diagnosis, which made prediction impossible. 
We prospectively studied unselected patients by using 
rigorous diagnostic criteria to minimize recall, selection, 
and diagnostic verifi cation bias.
A limitation of serologic testing is that serologic cross-
reactions occur between dengue and other fl aviviruses, but 
we believe this is unlikely to bias our results. West Nile 
virus has not been described in the region, yellow fever 
is not present in Asia, and Japanese encephalitis is of low 
endemicity, with no recent outbreaks reported in the area. 
Furthermore, we used dengue virus neutralization testing to 
confi rm the specifi c presence of dengue in a subset of IgG-
positive serum samples in addition to performing PCR and 
viral isolation on the acute-phase serum samples of patients 
with serologically confi rmed acute dengue. The median 
duration of fever in those in whom virus was isolated is 
consistent with the reported persistence of viremia for 5–6 
days after onset of symptoms (1,30). Because most patients 
were adults, we could not compare the clinical features of 
symptomatic dengue in adults versus those in children. 
We have not delineated the full clinical spectrum of 
dengue, which would require a prospective population-
based study. However, we believe that the population 
studied is representative of patients in the region with 
clinically noteworthy symptomatic dengue: Teaching 
Hospital Karapitiya has a large catchment area and is 1 of 
2 public teaching hospitals in the Southern Province, and 
there are no large private hospitals in the area. Patients with 
fulminant dengue may die before hospital evaluation, but 
most, including indigent patients from outlying areas, seek 
care because of free access.
In summary, we found that dengue is responsible 
for 6.3% of undifferentiated febrile illnesses in southern 
Sri Lanka. We identifi ed relatively mild disease, despite 
identifying mostly serotype DEN3 infection, which is 
diffi cult to distinguish from other acute febrile illnesses, 
and we found acute infections were mostly in young adults. 
We hypothesize that the burden and spectrum of acute 
dengue is under-recognized in other regions because of 
limited study and limited tools for rapid diagnosis. Clinical 
recognition is poor for less severe dengue, particularly, 
perhaps, when endemicity is low or transmission is 
sporadic. Assays to measure antibody in single serum 
samples may be misleading, especially early in illness, and 
PCR and viral isolation are often unavailable and may be 
insensitive. Other causes of acute febrile illness require 
antimicrobial drug therapies, but dengue only requires 
supportive care; thus, improved low-cost diagnostic tools 
are urgently needed to guide clinical management.
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